Therakos, INO Therapeutics LLC, Sucampo Pharmaceuticals, Inc., Questcor Pharmaceuticals, Cadence Pharmaceuticals
United Kingdom
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk


Mallinckrodt, a pharmaceutical company, has not publicly terminated business relationships based on views or beliefs. Mallinckrodt scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Mallinckrodt increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Mallinckrodt forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. The company does not provide viewpoint protections for its employees. Mallinckrodt has donated to the Equality PAC and the LGBTQ Victory Fund, which is a national organization dedicated to electing LGBTQ+ people who can further LGBTQ issues at all levels of government. The company actively sponsors local and national organizations that advocate for LGBTQ issues. Mallinckrodt supported the federal Equality Act, advocated against state legislation designed to protect girls' sports and other similar gender-based issues, and is a corporate partner of the National LGBT Chamber of Commerce (NGLCC). The company supports ESG within its business practices and discriminates against some religious organizations in its charitable giving. For these reasons, Mallinckrodt receives a High Risk rating.

Generate Reports